Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

作者: Despina Handolias , Renato Salemi , William Murray , Angela Tan , Wendy Liu

DOI: 10.1111/J.1755-148X.2010.00671.X

关键词:

摘要: In melanoma, mutations in KIT are most frequent acral and mucosal subtypes rarely reported cutaneous melanomas particularly those associated with intermittent UV exposure. Conversely arising within chronic sun damaged skin considered to harbour at higher rates. To characterize the frequency of a representative melanoma population, 261 patients from two Australian centres were prospectively screened for exons 11, 13 17 gene. A total 257 had non-acral sites four melanomas. No or ocular analysed. identified five tumours (2% entire cohort) including Two three markers damage as assessed by degree elastosis. remaining cohort, 43% chronically skin. This report confirms that an infrequent both exposed

参考文章(28)
S. Nishikawa, M. Kusakabe, K. Yoshinaga, M. Ogawa, S. Hayashi, T. Kunisada, T. Era, T. Sakakura, S. Nishikawa, In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development. The EMBO Journal. ,vol. 10, pp. 2111- 2118 ,(1991) , 10.1002/J.1460-2075.1991.TB07744.X
Punita Dhawan, Ann Richmond, Amar B. Singh, Darrel L. Ellis, Constitutive Activation of Akt/Protein Kinase B in Melanoma Leads to Up-Regulation of Nuclear Factor-κB and Tumor Progression Cancer Research. ,vol. 62, pp. 7335- 7342 ,(2002)
Nancy E. Thomas, BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Research. ,vol. 16, pp. 97- 103 ,(2006) , 10.1097/01.CMR.0000215035.38436.87
John A. Curtin, Jane Fridlyand, Toshiro Kageshita, Hetal N. Patel, Klaus J. Busam, Heinz Kutzner, Kwang-Hyun Cho, Setsuya Aiba, Eva-Bettina Bröcker, Philip E. LeBoit, Dan Pinkel, Boris C. Bastian, Distinct Sets of Genetic Alterations in Melanoma The New England Journal of Medicine. ,vol. 353, pp. 2135- 2147 ,(2005) , 10.1056/NEJMOA050092
F. Stephen Hodi, Philip Friedlander, Christopher L. Corless, Michael C. Heinrich, Suzanne Mac Rae, Andrea Kruse, Jyothi Jagannathan, Annick D. Van den Abbeele, Elsa F. Velazquez, George D. Demetri, David E. Fisher, Major Response to Imatinib Mesylate in KIT-Mutated Melanoma Journal of Clinical Oncology. ,vol. 26, pp. 2046- 2051 ,(2008) , 10.1200/JCO.2007.14.0707
Marcia L. Taylor, Dean D. Metcalfe, Kit signal transduction. Hematology-oncology Clinics of North America. ,vol. 14, pp. 517- 535 ,(2000) , 10.1016/S0889-8588(05)70294-X
Ken Wyman, Michael B. Atkins, Victor Prieto, Omar Eton, David F. McDermott, Francie Hubbard, Christine Byrnes, Kathleen Sanders, Jeffrey A. Sosman, Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. ,vol. 106, pp. 2005- 2011 ,(2006) , 10.1002/CNCR.21834
K B Kim, O Eton, D W Davis, M L Frazier, D J McConkey, A H Diwan, N E Papadopoulos, A Y Bedikian, L H Camacho, M I Ross, J N Cormier, J E Gershenwald, J E Lee, P F Mansfield, L A Billings, C S Ng, C Charnsangavej, M Bar-Eli, M M Johnson, A J Murgo, V G Prieto, Phase II trial of imatinib mesylate in patients with metastatic melanoma British Journal of Cancer. ,vol. 99, pp. 734- 740 ,(2008) , 10.1038/SJ.BJC.6604482
Jose Lutzky, Juergen Bauer, Boris C. Bastian, Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell & Melanoma Research. ,vol. 21, pp. 492- 493 ,(2008) , 10.1111/J.1755-148X.2008.00475.X
J. Grabbe, P. Welker, E. Dippel, B. M. Czarnetzki, Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes Archives of Dermatological Research. ,vol. 287, pp. 78- 84 ,(1994) , 10.1007/BF00370723